CSG’s Ukraine Ammo Coalition Shrinks to Nine as Political Winds Shift; Stock Punished Despite Record Orders and Chemical-Cum-Fuse Pivot

Czech industrial group CSG's stock dives 56.7% from peak as half of Ukraine ammo coalition drops out; yet €17B order book and new ventures in chemicals, fuses, and Ukraine production signal resilience.

The Czechoslovak Group finds itself caught between a crumbling political coalition and a punishing equity market, even as its order books swell and new industrial ventures take shape. The company’s stock has shed more than 14% in a single week, trading near 15.53 euros at one point before closing Thursday at 15.62 euros — a staggering 56.7% below its 52-week peak of 36.05 euros and close to multi-year lows.

The most immediate headwind is political. Half of the 18 countries that originally backed the Czech?led initiative to finance artillery munitions for Ukraine have pulled out. Czech President Petr Pavel confirmed the exodus, blaming the return of Andrej Babiš as prime minister for removing the domestic political support the programme once enjoyed. The initiative currently supplies roughly half of all artillery shells that allies deliver to Kyiv, and since its launch in 2024 it has shipped more than four million rounds — with CSG serving as the prime contractor. Pavel, warning of a heavier burden on the remaining states, plans to put the issue on the agenda of the NATO summit in Ankara, Turkey, in early July. Some former participants are already bypassing Prague and buying ammunition directly for Ukraine.

Yet the company is not standing still. It has embarked on a multi?pronged diversification strategy that spans chemicals, fuse production and local manufacturing in Ukraine.

In the past week, CSG secured an economic stake of 20.1% in the German specialty chemicals group Alzchem. Of that, 9.9% is held directly through its subsidiary Staluna Trade, while a further 10.2% is channelled via total?return swaps that run until May 2027 — giving CSG economic exposure without triggering full voting?rights disclosure thresholds. Alzchem produces nitrocellulose, a critical ingredient for propellant charges in munitions. The move has raised governance eyebrows among some market watchers, but Alzchem’s management, which employs around 1,700 people, has downplayed concerns, insisting the existing strategy remains unchanged.

On the military side, CEO Michal Strnad is pushing vertical integration. CSG has signed two long?term contracts with European NATO member states for the supply of fuses for large?calibre ammunition, worth a combined amount in the higher double?digit million euro range. To deliver on those deals, the group has set up a new joint venture, Fuchs Electronics Europe, together with South African partner Reunert. Production of both mechanical and electronic fuses will be housed in a new facility in Dubnica nad Váhom, Slovakia, with a target of ramping up output by 2026. Separately, CSG has launched licensed production of large?calibre ammunition inside Ukraine in partnership with Ukrainska Bronetechnika (Ukrainian Armor), providing the know?how and key components to strengthen Kyiv’s domestic manufacturing capacity.

Underlying all this, the operating numbers are impressive. CSG’s order backlog has hit 17 billion euros, with a further 27 billion euros in the pipeline, bringing total potential business to 44 billion euros. Revenue climbed 13.8% to 1.54 billion euros, while operating EBIT rose 8.7% to 372 million euros, yielding a margin of 24.1%. Management has reaffirmed its 2026 revenue target of 7.4–7.6 billion euros, and plans to produce 1.1 million large?calibre shells annually by 2028. At the end of the first quarter, capacity already exceeded 800,000 units.

Despite that operational momentum, the stock has been hammered. The immediate trigger was a report from short?seller Hunterbrook, which used corporate register data from the Czech Republic, Slovakia and Spain to question not just CSG’s management but the entire business model. The company has denied the allegations. The technical picture is equally grim: the relative strength index stands at 34, signalling continued downward pressure, while the 30?day annualised volatility has spiked to 78%.

Yet analysts are unanimous in their bullishness. All ten covering the stock rate it a buy, with an average price target of 32.45 euros — more than double the current level. The gap between CSG’s strategic and financial muscle and its market valuation remains as wide as ever. Whether the NATO summit in Ankara can restore political confidence in the ammunition initiative — and help close that gap — will be the key question for the weeks ahead.